Abstract #0772
Pulmonary Functional MRI to Phenotype COPD and Evaluate Treatment Efficacy: Intermediate Endpoints and Predictors of Efficacy when Conventional endpoints fail?
Sarah Svenningsen 1,2 , Gregory Paulin 1,2 , Miranda Kirby 1,2 , Nikhil Kanhere 1,3 , Roya Etemad-Rezai 4 , David G McCormack 5 , and Grace Parraga 1,2
1
Imaging Research Laboratories, Robarts
Research Institute, London, Ontario, Canada,
2
Department
of Medical Biophysics, The University of Western
Ontario, London, Ontario, Canada,
3
Graduate
Program in Biomedical Engineering, The University of
Western Ontario, London, Ontario, Canada,
4
Department
of Medical Imaging, The University of Western Ontario,
London, Ontario, Canada,
5
Department
of Medicine, The University of Western Ontario, London,
Ontario, Canada
In subjects with advanced COPD, we evaluated
hyperpolarized
3
He
MRI measurements of emphysema and airways disease in a
study of the 4-week treatment efficacy of a handheld
airway clearance device for mobilizing mucous
secretions. Whereas all subjects reported a modest
improvement in ease of clearing mucous following
therapy, 6/14 subjects showed improved
3
He
MRI ventilation (p=0.04), with concomitantly improved
forced vital capacity and 6MWD, and this was not
observed in imaging non-responders. In addition, imaging
measurements of emphysema was a negative-predictor of
response. Non-invasive imaging measurements of COPD can
be used as intermediate endpoints and phenotypes in
therapy trials.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
